Acute Coronary Syndrome

News Acute Coronary Syndrome

• Ablynx reports phase II dara for ALX-0081 in high risk ACS patients undergoing a PCI procedure

  Ablynx  announced head-line data from a proof-of-concept (POC) Phase II study with the anti-vWF Nanobody, ALX-0081, in high risk patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In this multi-national, multi-institutional, open-label Phase II study, Ab more

• First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204

  BioInvent International AB  announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.The Phase II study is a multicenter, rand more

• BioInvent announces approval to start Phase II trial for its novel cardiovascular drug BI-204

  BioInvent International AB announced IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory more

Publications Acute Coronary Syndrome

• The next 10 years in interventional cardiology

  Interview by Louise Rishton, Commissioning Editor Gregg Stone is Professor of Medicine at Columbia University, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapies at Columbia University Medical Center, and Co-Director of Medical Education and Researc more

• Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent

  Summary Dual antiplatelet therapy is essential for the management of acute coronary syndrome. In particular, combination therapy using aspirin with a platelet ADP (i.e. P2Y12) receptor inhibitor, such as clopidogrel, prasugrel or, more recently, ticagrelor, has been recommended for patients with more

• Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome

  While outcomes for ST-segment-elevation myocardial infarction has significantly decreased over the last years, patients presenting with non-ST-segment-elevation acute coronary syndromes (NSTEACS) still have a rather high mortality. Longer term mortality over 4 years is about double the mortality aft more

Market studies Acute Coronary Syndrome

• Acute Coronary Syndrome – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Acute Coronary Syndrome - Pipeline Review, H2 2012', provides an overview of the Acute Coronary Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and speci more

• Italy Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: The pharmaceuticals and healthcare sector will be a target of further cost containment, particularly as National Health System (SSN) data for H111, which shows a decline in spending, highlights the success of previous cost-containment efforts. Headline Expenditure Projections ?? Pharmac more

• Acute Coronary Syndrome – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Acute Coronary Syndrome - Pipeline Review, H1 2012', provides an overview of the Acute Coronary Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and speci more

Websites Acute Coronary Syndrome